HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

A strategic collaboration will pair HCB101, a macrophage CD47-SIRPα blockade, with Aston Sci's Phase 2 HER2-directed DNA vaccine AST-301 to pursue durable innate and adaptive antitumor immunity. Initial studies will focus on gastric and breast cancers; the article excerpt provides no efficacy results or further details on the expanded evaluation.